Core Viewpoint - The company, He Yu-B (02256), has seen a significant stock price increase following the approval of its IND application for the oral PD-L1 inhibitor ABSK043 in combination with the KRAS G12C inhibitor, Goresan, for treating KRAS G12C mutated NSCLC in China, marking a progression to Phase II clinical trials. Additionally, the company has been included in the MSCI Global Small Cap Index, which is expected to enhance its global funding visibility and liquidity [1]. Group 1 - The stock price of He Yu-B increased by over 6% in early trading, currently up 4.92% at HKD 17.93, with a trading volume of HKD 39.0714 million [1]. - The IND application for the combination treatment of ABSK043 and Goresan has been approved in China, allowing the drug to enter Phase II clinical trials [1]. - The inclusion in the MSCI Global Small Cap Index is anticipated to boost the company's global funding attention and positively impact liquidity [1]. Group 2 - CICC's research report highlights that ABSK043 has the potential to be a globally competitive oral small molecule PD-L1 inhibitor [1]. - The company’s strategy of combining oral therapies is expected to offer better patient compliance and safety profiles compared to the traditional injection plus oral combination [1]. - Future clinical developments of the combination treatment are deemed worthy of attention [1].

Core Viewpoint - The company, He Yu-B (02256), has seen a significant stock price increase following the approval of its IND application for the oral PD-L1 inhibitor ABSK043 in combination with the KRAS G12C inhibitor, Goreserib, for treating KRAS G12C mutated NSCLC in China, and its inclusion in the MSCI Global Small Cap Index [1] Group 1: Clinical Development - The IND application for the oral PD-L1 inhibitor ABSK043 in combination with Goreserib has been approved in China, allowing it to enter Phase II clinical trials [1] - The combination therapy targets KRAS G12C mutations in non-small cell lung cancer (NSCLC) [1] Group 2: Market Impact - The stock price of He Yu-B rose over 6% in early trading, with a current increase of 4.92%, reaching HKD 17.93, with a trading volume of HKD 39.0714 million [1] - Inclusion in the MSCI Global Small Cap Index is expected to enhance the company's global visibility and potentially improve liquidity [1] Group 3: Analyst Insights - CICC's report highlights ABSK043 as a promising oral small molecule PD-L1 inhibitor with global potential [1] - The oral + oral combination therapy is anticipated to offer better patient compliance and safety profile compared to injection + oral combinations, warranting attention on future clinical developments [1]

Group 1 - The company maintains its net profit forecast for 2025 and 2026 at 48 million and 320 million respectively, while upgrading the target price by 33.3% to 20.0 HKD, indicating an upside potential of 18.3% from the current stock price [1] - The company announced the approval of its IND application for the oral PD-L1 inhibitor ABSK043 in combination with the KRAS G12C inhibitor for treating KRAS G12C mutated NSCLC in China, and it has been included in the MSCI global small-cap index [2][4] - ABSK043 is a promising oral small molecule PD-L1 inhibitor with good bioavailability and selectivity, showing good safety and anti-tumor activity in phase I studies, and is currently entering phase II clinical trials in combination with the KRAS G12C inhibitor [3] Group 2 - Being included in the MSCI global small-cap index is expected to enhance the company's visibility and liquidity, positively impacting global fund attention [4]